FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311807675> ?p ?o ?g. }

• W4311807675 endingPage "12" @default.
• W4311807675 startingPage "1" @default.
• W4311807675 abstract "Background. The ability of vaccine-induced antibodies to bind C1q could affect pathogen neutralization. In this study, we investigated C1q binding and subsequent complement activation by anti-spike (S) protein receptor-binding domain (RBD) specific antibodies produced following vaccination with either the mRNA vaccine BNT162b2 or the inactivated vaccine BBIBP-CorV. Methods. Serum samples were collected in the period of July 2021-March 2022. Participants’ demographic data, type of vaccine, date of vaccination, as well as adverse effects of the vaccine were recorded. The serum samples were incubated with S protein RBD-coated plates. Levels of human IgG, IgA, IgM, C1q, and mannose-binding lectin (MBL) that were bound to the plate, as well as formed C3d, and C5b-9 were compared between different groups of participants. Results. A total of 151 samples were collected from vaccinated ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>n</mi> <mo>=</mo> <mn>116</mn> </math> ) and nonvaccinated ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>n</mi> <mo>=</mo> <mn>35</mn> </math> ) participants. Participants who received either one or two doses of BNT162b2 formed higher levels of anti-RBD IgG and IgA than participants who received BBIBP-CorV. The anti-RBD IgG formed following either vaccine bound C1q, but significantly more C1q binding was observed in participants who received BNT162b2. Subsequently, C5b-9 formation was significantly higher in participants who received BNT162b2, while no significant difference in C5b-9 formation was found between the nonvaccinated and BBIBP-CorV groups. The formation of C5b-9 was strongly correlated to C1q binding and not to MBL binding, additionally, the ratio of formed C5b-9/bound C1q was significantly higher in the BNT162b2 group. Conclusion. Anti-RBD IgG formed following vaccination can bind C1q with subsequent complement activation, and the degree of terminal complement pathway activation differed between vaccines, which could play a role in the protection offered by COVID-19 vaccines. Further investigation into the correlation between vaccine protection and vaccine-induced antibodies’ ability to activate complement is required." @default.
• W4311807675 created "2022-12-28" @default.
• W4311807675 creator A5013599807 @default.
• W4311807675 creator A5017121649 @default.
• W4311807675 creator A5024251437 @default.
• W4311807675 creator A5036800613 @default.
• W4311807675 creator A5054681799 @default.
• W4311807675 date "2022-12-17" @default.
• W4311807675 modified "2023-09-26" @default.
• W4311807675 title "Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement" @default.
• W4311807675 cites W1986592145 @default.
• W4311807675 cites W2009959546 @default.
• W4311807675 cites W2014538668 @default.
• W4311807675 cites W2021004292 @default.
• W4311807675 cites W2025189810 @default.
• W4311807675 cites W2027091459 @default.
• W4311807675 cites W2060166744 @default.
• W4311807675 cites W2137834917 @default.
• W4311807675 cites W2140590997 @default.
• W4311807675 cites W2167279371 @default.
• W4311807675 cites W2169656611 @default.
• W4311807675 cites W2425420867 @default.
• W4311807675 cites W2949131782 @default.
• W4311807675 cites W3009335299 @default.
• W4311807675 cites W3011537081 @default.
• W4311807675 cites W3027964178 @default.
• W4311807675 cites W3029338293 @default.
• W4311807675 cites W3033022675 @default.
• W4311807675 cites W3035898754 @default.
• W4311807675 cites W3036101703 @default.
• W4311807675 cites W3048558989 @default.
• W4311807675 cites W3079498584 @default.
• W4311807675 cites W3086741758 @default.
• W4311807675 cites W3093786419 @default.
• W4311807675 cites W3117773316 @default.
• W4311807675 cites W3173122711 @default.
• W4311807675 cites W3173200288 @default.
• W4311807675 cites W3176668337 @default.
• W4311807675 cites W3202826390 @default.
• W4311807675 cites W3204737766 @default.
• W4311807675 cites W3204989207 @default.
• W4311807675 cites W3209397507 @default.
• W4311807675 cites W3216880904 @default.
• W4311807675 cites W3217223441 @default.
• W4311807675 cites W4205251131 @default.
• W4311807675 cites W4210332259 @default.
• W4311807675 cites W4213221851 @default.
• W4311807675 cites W4213256071 @default.
• W4311807675 cites W4220818213 @default.
• W4311807675 cites W4283516548 @default.
• W4311807675 doi "https://doi.org/10.1155/2022/7263740" @default.
• W4311807675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36573216" @default.
• W4311807675 hasPublicationYear "2022" @default.
• W4311807675 type Work @default.
• W4311807675 citedByCount "1" @default.
• W4311807675 countsByYear W43118076752023 @default.
• W4311807675 crossrefType "journal-article" @default.
• W4311807675 hasAuthorship W4311807675A5013599807 @default.
• W4311807675 hasAuthorship W4311807675A5017121649 @default.
• W4311807675 hasAuthorship W4311807675A5024251437 @default.
• W4311807675 hasAuthorship W4311807675A5036800613 @default.
• W4311807675 hasAuthorship W4311807675A5054681799 @default.
• W4311807675 hasBestOaLocation W43118076751 @default.
• W4311807675 hasConcept C104317684 @default.
• W4311807675 hasConcept C112313634 @default.
• W4311807675 hasConcept C126322002 @default.
• W4311807675 hasConcept C127716648 @default.
• W4311807675 hasConcept C159047783 @default.
• W4311807675 hasConcept C159654299 @default.
• W4311807675 hasConcept C185592680 @default.
• W4311807675 hasConcept C188082640 @default.
• W4311807675 hasConcept C203014093 @default.
• W4311807675 hasConcept C22070199 @default.
• W4311807675 hasConcept C2779134260 @default.
• W4311807675 hasConcept C3007834351 @default.
• W4311807675 hasConcept C3008058167 @default.
• W4311807675 hasConcept C524204448 @default.
• W4311807675 hasConcept C55493867 @default.
• W4311807675 hasConcept C71924100 @default.
• W4311807675 hasConceptScore W4311807675C104317684 @default.
• W4311807675 hasConceptScore W4311807675C112313634 @default.
• W4311807675 hasConceptScore W4311807675C126322002 @default.
• W4311807675 hasConceptScore W4311807675C127716648 @default.
• W4311807675 hasConceptScore W4311807675C159047783 @default.
• W4311807675 hasConceptScore W4311807675C159654299 @default.
• W4311807675 hasConceptScore W4311807675C185592680 @default.
• W4311807675 hasConceptScore W4311807675C188082640 @default.
• W4311807675 hasConceptScore W4311807675C203014093 @default.
• W4311807675 hasConceptScore W4311807675C22070199 @default.
• W4311807675 hasConceptScore W4311807675C2779134260 @default.
• W4311807675 hasConceptScore W4311807675C3007834351 @default.
• W4311807675 hasConceptScore W4311807675C3008058167 @default.
• W4311807675 hasConceptScore W4311807675C524204448 @default.
• W4311807675 hasConceptScore W4311807675C55493867 @default.
• W4311807675 hasConceptScore W4311807675C71924100 @default.
• W4311807675 hasFunder F4320310068 @default.
• W4311807675 hasLocation W43118076751 @default.
• W4311807675 hasLocation W43118076752 @default.

• next